Department of Biochemistry, the Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin 300071, China.
Acta Pharmacol Sin. 2011 Jul;32(7):921-9. doi: 10.1038/aps.2011.40. Epub 2011 Jun 6.
To investigate the endogenous signaling pathways associated with high proliferation potential of breast cancer cells.
Breast cancer cell lines LM-MCF-7 and MCF-7 with high and low proliferation capability were used. The promoter activity of fatty acid synthase (FASN) was examined using luciferase reporter gene assay. The expression level of FASN mRNA was measured using RT-PCR and real time PCR, respectively. The level of leukotriene B4 (LTB4) was determined with ELISA. The expression levels of 5-lipoxygenase (5-LOX) was analyzed using RT-PCR and Western blot, respectively. 5-Bromo-20-deoxyuridine (BrdU) incorporation assay was used to study the proliferation of LM-MCF-7 and MCF-7 cells.
The promoter activity of FASN was significantly higher in LM-MCF-7 cells than MCF-7 cells. Treatment of LM-MCF-7 cells with ERK1/2 inhibitor PD98059 (30-50 μmol/L) or LOX inhibitor NDGA (25 μmol/L) abolished the activation of FASN. Moreover, treatment of LM-MCF-7 cells with the specific 5-LOX inhibitor MK-886 (20-40 μmol/L) or 5-LOX siRNA (50-100 nmol/L) decreased the promoter activity of FASN. The level of LTB4, the final metabolite produced by 5-LOX, was significantly higher in LM-MCF-7 cells than MCF-7 cells. Administration of exogenous LTB4 (1-10 nmol/L) was able to stimulate the promoter activity of FASN in MCF-7 cells. Treatment of LM-MCF-7 cells with the FASN inhibitor cerulenin (10 μmol/L) reduced all the levels of p-ERK1/2, 5-LOX, and LTB4. Treatment of LM-MCF-7 cells with cerulenin, PD98059, or MK-886 abolished the proliferation. Administration of exogenous LTB4 (10 nmol/L) significantly increased BrdU incorporation in MCF-7 cells.
THESE results suggest a novel positive feedback loop involving FASN/p-ERK1/2/5-LOX/LTB4/FASN contributes to the sustaining growth of breast cancer LM-MCF-7 cells.
研究与乳腺癌细胞高增殖潜能相关的内源性信号通路。
使用具有高增殖能力和低增殖能力的乳腺癌细胞系 LM-MCF-7 和 MCF-7。使用荧光素酶报告基因检测法检测脂肪酸合酶(FASN)的启动子活性。分别采用 RT-PCR 和实时 PCR 检测 FASN mRNA 的表达水平。用 ELISA 法测定白三烯 B4(LTB4)的水平。分别采用 RT-PCR 和 Western blot 分析 5-脂氧合酶(5-LOX)的表达水平。采用 5-溴-20-脱氧尿苷(BrdU)掺入法研究 LM-MCF-7 和 MCF-7 细胞的增殖情况。
LM-MCF-7 细胞中 FASN 的启动子活性明显高于 MCF-7 细胞。用 ERK1/2 抑制剂 PD98059(30-50 μmol/L)或 LOX 抑制剂 NDGA(25 μmol/L)处理 LM-MCF-7 细胞可消除 FASN 的激活。此外,用特异性 5-LOX 抑制剂 MK-886(20-40 μmol/L)或 5-LOX siRNA(50-100 nmol/L)处理 LM-MCF-7 细胞可降低 FASN 的启动子活性。LM-MCF-7 细胞中 LTB4 的水平,即 5-LOX 的终产物,明显高于 MCF-7 细胞。外源性 LTB4(1-10 nmol/L)可刺激 MCF-7 细胞中 FASN 的启动子活性。用 FASN 抑制剂 cerulenin(10 μmol/L)处理 LM-MCF-7 细胞可降低所有 p-ERK1/2、5-LOX 和 LTB4 的水平。用 cerulenin、PD98059 或 MK-886 处理 LM-MCF-7 细胞可抑制增殖。外源性 LTB4(10 nmol/L)可显著增加 MCF-7 细胞中的 BrdU 掺入。
这些结果表明,涉及 FASN/p-ERK1/2/5-LOX/LTB4/FASN 的新型正反馈回路有助于维持乳腺癌 LM-MCF-7 细胞的生长。